These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38285771)

  • 41. Effect of diabetes on neurological adverse effects and chemotherapy induced peripheral neuropathy in advanced colorectal cancer patients treated with different FOLFOX regimens.
    Bano N; Ikram R
    Pak J Pharm Sci; 2019 Jan; 32(1):125-130. PubMed ID: 30772800
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of metformin on the survival of colorectal cancer patients with type 2 diabetes mellitus.
    Tarhini Z; Manceur K; Magne J; Mathonnet M; Jost J; Christou N
    Sci Rep; 2022 Jul; 12(1):12374. PubMed ID: 35859114
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Two variants on T2DM susceptible gene HHEX are associated with CRC risk in a Chinese population.
    Sun R; Liu JP; Gao C; Xiong YY; Li M; Wang YP; Su YW; Lin M; Jiang AL; Xiong LF; Xie Y; Feng JP
    Oncotarget; 2016 May; 7(20):29770-9. PubMed ID: 27105501
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Survival of Colorectal Cancer Patients With Diabetes Mellitus: A Meta-Analysis.
    Petrelli F; Ghidini M; Rausa E; Ghidini A; Cabiddu M; Borgonovo K; Ghilardi M; Parati MC; Pietrantonio F; Sganzerla P; Bossi AC
    Can J Diabetes; 2021 Mar; 45(2):186-197.e2. PubMed ID: 33039329
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlation of serum IGF-1, AGEs and their receptors with the risk of colorectal cancer in patients with type 2 diabetes mellitus.
    Chen Z; Hong Q
    Front Oncol; 2023; 13():1125745. PubMed ID: 36890832
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer.
    Moreno-Solórzano I; Ibeas-Rollan R; Monzó-Planella M; Moreno-Solórzano J; Martínez-Ródenas F; Pou-Sanchis E; Hernández-Borlan R; Navarro-Vigo M; Ortigosa-Rodríguez S; Gel-Moreno B
    Clin Colorectal Cancer; 2007 Sep; 6(9):634-40. PubMed ID: 17945035
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis.
    Mei ZB; Zhang ZJ; Liu CY; Liu Y; Cui A; Liang ZL; Wang GH; Cui L
    PLoS One; 2014; 9(3):e91818. PubMed ID: 24647047
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sex-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients.
    Park JW; Lee JH; Park YH; Park SJ; Cheon JH; Kim WH; Kim TI
    World J Gastroenterol; 2017 Jul; 23(28):5196-5205. PubMed ID: 28811714
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study.
    Janinis J; Papakostas P; Samelis G; Skarlos D; Papagianopoulos P; Fountzilas G
    Ann Oncol; 2000 Feb; 11(2):163-7. PubMed ID: 10761750
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of
    Mitroi AF; Leopa N; Dumitru E; Brînzan C; Tocia C; Dumitru A; Popescu RC
    Genes (Basel); 2022 Jul; 13(8):. PubMed ID: 35893034
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Type 2 diabetes impacts colorectal adenoma detection in screening colonoscopy.
    Ottaviano LF; Li X; Murray M; Frye JT; Lung BE; Zhang YY; Yang J; Taub EM; Bucobo JC; Buscaglia JM; Li E; Miller JD
    Sci Rep; 2020 May; 10(1):7793. PubMed ID: 32385343
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin.
    Fontana E; Meyers J; Sobrero A; Iveson T; Shields AF; Taieb J; Yoshino T; Souglakos I; Smyth EC; Lordick F; Moehler M; Giraut A; Harkin A; Labianca R; Meyerhardt J; André T; Boukovinas I; Lonardi S; Saunders M; Vernerey D; Oki E; Georgoulias V; Ben-Aharon I; Shi Q
    J Clin Oncol; 2021 Dec; 39(36):4009-4019. PubMed ID: 34752136
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metagenomic and targeted metabolomic analyses reveal distinct phenotypes of the gut microbiota in patients with colorectal cancer and type 2 diabetes mellitus.
    Yang Y; Han Z; Gao Z; Chen J; Song C; Xu J; Wang H; Huang A; Shi J; Gu J
    Chin Med J (Engl); 2023 Dec; 136(23):2847-2856. PubMed ID: 36959686
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of type 2 diabetes mellitus on short-term and long-term outcomes of patients with esophageal squamous cell cancer undergoing resection: a propensity score analysis.
    Yao W; Meng Y; Lu M; Fan W; Huang J; Li J; Zhu Z
    Cancer Commun (Lond); 2018 Apr; 38(1):14. PubMed ID: 29764483
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG).
    Degirmencioglu S; Tanriverdi O; Menekse S; Dogan M; Hacıoglu B; Oktay E; Erdem D; Arpaci E; Uluc BO; Turhal S; Yilmaz M; Pilanci KN; Sakin A; Araz M; Cokmert S; Ozdemir O; Sen E; Nayir E
    J BUON; 2019; 24(1):136-142. PubMed ID: 30941962
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Abdel-Rahman O
    Clin Colorectal Cancer; 2019 Dec; 18(4):e385-e393. PubMed ID: 31378656
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial.
    Bridgewater JA; Pugh SA; Maishman T; Eminton Z; Mellor J; Whitehead A; Stanton L; Radford M; Corkhill A; Griffiths GO; Falk S; Valle JW; O'Reilly D; Siriwardena AK; Hornbuckle J; Rees M; Iveson TJ; Hickish T; Garden OJ; Cunningham D; Maughan TS; Primrose JN;
    Lancet Oncol; 2020 Mar; 21(3):398-411. PubMed ID: 32014119
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer.
    Cecchini M; Kortmansky JS; Cui C; Wei W; Thumar JR; Uboha NV; Hafez N; Lacy J; Fischbach NA; Sabbath KD; Gomez CM; Sporn JR; Stein S; Hochster HS
    Cancer; 2021 May; 127(9):1417-1424. PubMed ID: 33351187
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The occurrence and impact on survival of type 2 diabetes mellitus and thrombocytosis in colorectal cancer, before and after the surgical resection of the primary tumor].
    Herold Z; Ambrus V; Herold M; Herczeg G; Igaz P; Harsányi L; Somogyi A
    Orv Hetil; 2018 May; 159(19):756-767. PubMed ID: 29730943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.